1887
Research Open Access
Like 0

Abstract

Background

To increase the acceptability of influenza vaccine, it is important to quantify the overall benefits of the vaccination programme.

Aim

To assess the impact of influenza vaccination in Portugal, Spain and the Netherlands, we estimated the number of medically attended influenza-confirmed cases (MAICC) in primary care averted in the seasons 2015/16 to 2017/18 among those ≥ 65 years.

Methods

We used an ecological approach to estimate vaccination impact. We compared the number of observed MAICC (n) to the estimated number that would have occurred without the vaccination programme (N). To estimate N, we used: (i) MAICC estimated from influenza surveillance systems, (ii) vaccine coverage, (iii) pooled (sub)type-specific influenza vaccine effectiveness estimates for seasons 2015/16 to 2017/18, weighted by the proportion of virus circulation in each season and country. We estimated the number of MAICC averted (NAE) and the prevented fraction (PF) by the vaccination programme.

Results

The annual average of NAE in the population ≥ 65 years was 33, 58 and 204 MAICC per 100,000 in Portugal, Spain and the Netherlands, respectively. On average, influenza vaccination prevented 10.7%, 10.9% and 14.2% of potential influenza MAICC each season in these countries. The lowest PF was in 2016/17 (4.9–6.1%) with an NAE ranging from 24 to 69 per 100,000.

Conclusions

Our results suggest that influenza vaccination programmes reduced a substantial number of MAICC. Together with studies on hospitalisations and deaths averted by influenza vaccination programmes, this will contribute to the evaluation of the impact of vaccination strategies and strengthen public health communication.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.45.1900268
2019-11-07
2019-11-13
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.45.1900268
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/45/eurosurv-24-45-5.html?itemId=/content/10.2807/1560-7917.ES.2019.24.45.1900268&mimeType=html&fmt=ahah

References

  1. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285-300.  https://doi.org/10.1016/S0140-6736(17)33293-2  PMID: 29248255 
  2. Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respir Viruses. 2018;12(1):132-7.  https://doi.org/10.1111/irv.12486  PMID: 29446233 
  3. World Health Organization. Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87(47):461-76. PMID: 23210147 
  4. World Health Organization (WHO). The Global Action Plan for influenza vaccines: report of the tenth meeting of the Advisory Group of the WHO Global Action Plan for Influenza Vaccines. Geneva: WHO; 2015. Available from: https://apps.who.int/iris/handle/10665/182733
  5. Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber J, et al. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Euro Surveill. 2014;19(16):20780.  https://doi.org/10.2807/1560-7917.ES2014.19.16.20780  PMID: 24786262 
  6. Jorgensen P, Mereckiene J, Cotter S, Johansen K, Tsolova S, Brown C. How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. Vaccine. 2018;36(4):442-52.  https://doi.org/10.1016/j.vaccine.2017.12.019  PMID: 29287683 
  7. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014;19(6):20701.  https://doi.org/10.2807/1560-7917.ES2014.19.6.20701  PMID: 24556348 
  8. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016;21(7):30139.  https://doi.org/10.2807/1560-7917.ES.2016.21.7.30139  PMID: 26924024 
  9. Foppa IM, Cheng P-Y, Reynolds SB, Shay DK, Carias C, Bresee JS, et al. Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14. Vaccine. 2015;33(26):3003-9.  https://doi.org/10.1016/j.vaccine.2015.02.042  PMID: 25812842 
  10. Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, et al. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine. 2018;36(10):1272-8.  https://doi.org/10.1016/j.vaccine.2018.01.045  PMID: 29402578 
  11. Kostova D, Reed C, Finelli L, Cheng P-Y, Gargiullo PM, Shay DK, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLoS One. 2013;8(6):e66312.  https://doi.org/10.1371/journal.pone.0066312  PMID: 23840439 
  12. Bonmarin I, Belchior E, Lévy-Bruhl D. Impact of influenza vaccination on mortality in the French elderly population during the 2000-2009 period. Vaccine. 2015;33(9):1099-101.  https://doi.org/10.1016/j.vaccine.2015.01.023  PMID: 25604800 
  13. Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14(1):813.  https://doi.org/10.1186/1471-2458-14-813  PMID: 25103091 
  14. Integrated Monitoring of Vaccines in Europe (I-MOVE+). Protocol for joint report on measuring the impact of influenza vaccination programmes among the elderly population in Spain, Navarra, the Netherlands and Portugal. Paris: Epiconcept; 2018. Available from: https://docs.google.com/viewer?a=v&pid=sites&srcid=ZXBpY29uY2VwdC5mcnxpbW92ZXBsdXN8Z3g6NjI1NWQ4MjBjZWFlNzI3Yg
  15. Teirlinck AC, de Gier B, Meijer A, Donker G, de Lange M, Koppeschaar C, et al. The incidence of symptomatic infection with influenza virus in the Netherlands 2011/2012 through 2016/2017, estimated using Bayesian evidence synthesis. Epidemiol Infect. 2018;1-6. PMID: 30348244 
  16. Rodrigues AP, Fonseca RC, Matias-Dias C. Rede Médicos-Sentinela como Instrumento de Vigilância em Saúde. [General Practitioner Sentinel Network as a Tool of [Public] Health Surveillance]. Acta Med Port. 2016;29(1):5-9. Portuguese.  https://doi.org/10.20344/amp.5938  PMID: 26926891 
  17. Larrauri Cámara A, Jiménez-Jorge S, Simón Méndez L, de Mateo Ontañón SSistema de Vigilancia de Gripe en España (SVGE). Vigilancia de la pandemia de gripe (H1N1) 2009 en España. [Surveillance of influenza pandemic (H1N1)2009 in Spain]. Rev Esp Salud Publica. 2010;84(5):569-88. Spanish. PMID: 21203720 
  18. Donker G. NIVEL primary care database - sentinel practices 2015. Utrecht: Nivel; 2016. Available from: https://www.nivel.nl/sites/default/files/bestanden/Peilstations_2015_Engel.pdf
  19. Heins M, Hooiveld M, Korevaar J. Vaccine coverage Dutch National influenza prevention program 2017: brief monitor. Utrecht: Nivel; 2018. Available from: https://www.nivel.nl/nl/publicatie/vaccine-coverage-dutch-national-influenza-prevention-program-2017-brief-monitor
  20. de Sanidad M, Consumo y Bienestar S, de España G. [Ministry of Health, Consumer Affairs and Social Welfare, Spanish Government]. Evolución de cobertura de vacunación antigripal en población ≥ 65 años. España, temporadas 2009-2010 a 2018-2019. [Evolution of influenza vaccination coverage in the population ≥ 65 years. Spain, seasons 2009-2010toa 2018-2019]. Madrid: Gobierno de España; 2018. Spanish. Available from: http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/CoberturasVacunacion/Tabla4.pdf
  21. Machado A, Kislaya I, Torres AR, Neto M. Vacinação antigripal da população portuguesa, em 2016/2017 e 2017/2018: cobertura e caracteristicas do ato vacinal. [Influenza vaccination of the Portuguese population, in 2016/17 and 2017/18: coverage and characteristics of the vaccination programme]. Lisbon: Instituto Nacional de Saude Doutor Ricardo Jorge, IP; 2018. Portuguese. Available from: http://repositorio.insa.pt/bitstream/10400.18/5700/3/INSA_Relatorio_Vacinacao-antigripal-epocas-2016-2017_2017-2018.pdf
  22. Kissling E, Valenciano M, Pozo F, Vilcu A-M, Reuss A, Rizzo C, et al. I-MOVE/I-MOVE+ study team. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Influenza Other Respir Viruses. 2018;12(4):423-37.  https://doi.org/10.1111/irv.12520  PMID: 29125681 
  23. Kissling E. Low vaccine effectiveness against influenza A(H3N2) in Europe: Estimates from the I-MOVE multicentre case control study. European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE); 6-8 Nov 2017, Stockholm, Sweden.
  24. Kissling E. 2017/18 European influenza season: Disparate I-MOVE multicentre case control study estimates with A(H1N1), A(H3N2) and trivalent vaccine lineage-mismatched B/Yamagata influenza viruses circulating. European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE); 21-23 Nov 2018, Saint Julian’s, Malta.
  25. Caini S, Spreeuwenberg P, Kusznierz GF, Rudi JM, Owen R, Pennington K, et al. Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014. BMC Infect Dis. 2018;18(1):269.  https://doi.org/10.1186/s12879-018-3181-y  PMID: 29884140 
  26. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-51.  https://doi.org/10.1016/S1473-3099(16)00129-8  PMID: 27061888 
  27. Darvishian M, Dijkstra F, van Doorn E, Bijlsma MJ, Donker GA, de Lange MMA, et al. Influenza vaccine effectiveness in the Netherlands from 2003/2004 through 2013/2014: The importance of circulating influenza virus types and subtypes. PLoS One. 2017;12(1):e0169528.  https://doi.org/10.1371/journal.pone.0169528  PMID: 28068386 
  28. Jackson ML, Phillips CH, Benoit J, Jackson LA, Gaglani M, Murthy K, et al. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018;36(4):467-72.  https://doi.org/10.1016/j.vaccine.2017.12.014  PMID: 29249545 
  29. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44.  https://doi.org/10.1016/S1473-3099(11)70295-X  PMID: 22032844 
  30. Centers for Disease Control and Prevention (CDC). Estimated influenza illnesses and hospitalizations averted by influenza vaccination - United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2013;62(49):997-1000. PMID: 24336131 
  31. Centers for Disease Control and Prevention (CDC). 2016-2017 estimated influenza illnesses, medical visits, and hospitalizations averted by vaccination in the United States. Atlanta: CDC; 2018. Available from: https://www.cdc.gov/flu/about/disease/2016-17.htm
  32. Oliva J, Delgado-Sanz C, Larrauri ASpanish Influenza Surveillance System. Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010-2016. Influenza Other Respir Viruses. 2018;12(1):161-70.  https://doi.org/10.1111/irv.12499  PMID: 28960828 
  33. Peppa M, John Edmunds W, Funk S. Disease severity determines health-seeking behaviour amongst individuals with influenza-like illness in an internet-based cohort. BMC Infect Dis. 2017;17(1):238.  https://doi.org/10.1186/s12879-017-2337-5  PMID: 28359335 
  34. Ma W, Huo X, Zhou M. The healthcare seeking rate of individuals with influenza like illness: a meta-analysis. Infect Dis (Lond). 2018;50(10):728-35.  https://doi.org/10.1080/23744235.2018.1472805  PMID: 30009680 
  35. World Health Organization (WHO). Outpatient contacts per person per year. European Health for All database (HFA-DB). Geneva: WHO. [Accessed: 6 Dec 2018]. Available from: https://gateway.euro.who.int/en/indicators/hfa_543-6300-outpatient-contacts-per-person-per-year/
  36. de Almeida Simões J, Augusto GF, Fronteira I, Hernández-Quevedo C. Portugal: health system review. Health Syst Transit. 2017;19(2):1-184. PMID: 28485714 
  37. Bernal-Delgado E, Garcia-Armesto S, Oliva J, Sanchez Martinez FI, Repullo JR, Pena-Longobardo LM, et al. Spain: health system review. Health Syst Transit. 2018;20(2):1-179. PMID: 30277216 
  38. Kroneman M, Boerma W, van den Berg M, Groenewegen P, de Jong J, van Ginneken E. Netherlands: health system review. Health Syst Transit. 2016;18(2):1-240. PMID: 27467715 
  39. Eichner M, Schwehm M, Eichner L, Gerlier L. Direct and indirect effects of influenza vaccination. BMC Infect Dis. 2017;17(1):308.  https://doi.org/10.1186/s12879-017-2399-4  PMID: 28441935 
  40. Backer JA, Wallinga J, Meijer A, Donker GA, van der Hoek W, van Boven M. The impact of influenza vaccination on infection, hospitalisation and mortality in the Netherlands between 2003 and 2015. Epidemics. 2019;26:77-85.  https://doi.org/10.1016/j.epidem.2018.10.001  PMID: 30344024 
  41. Yin JK, Heywood AE, Georgousakis M, King C, Chiu C, Isaacs D, et al. Systematic review and meta-analysis of indirect protection afforded by vaccinating children against seasonal influenza: Implications for policy. Clin Infect Dis. 2017;65(5):719-28.  https://doi.org/10.1093/cid/cix420  PMID: 28475770 
  42. Pel JZS. (Pilot study of the frequency and aetiology of influenza-like illness in winter 1963-1964). Proefonderzoek naar de frequentie en de aetiologie van griepachtige ziekten in de winter 1963-1964. Huisarts Wet. 1965;86:321.
  43. European Commission. Commission Implementing Decision 2012/506/EU of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Official Journal of the European Union. 2012;55(3):L262/1--57. Available from: https://op.europa.eu/en/publication-detail/-/publication/10ed460f-0711-11e2-8e28-01aa75ed71a1/language-en
/content/10.2807/1560-7917.ES.2019.24.45.1900268
Loading

Data & Media loading...

Supplementary data

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error